Trial Profile
A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and PK of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Japanese and Caucasian Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2022
Price :
$35
*
At a glance
- Drugs Eflapegrastim (Primary) ; Pegfilgrastim
- Indications Neutropenia
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Hanmi Pharmaceutical
- 06 Jan 2022 Results assessing the the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of eflapegrastim following a single subcutaneous administration to healthy Japanese and Caucasian subjects, published in the Drugs in R and D.
- 02 May 2014 New trial record